[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112018070140A2 - sistema de distribuição - Google Patents

sistema de distribuição

Info

Publication number
BR112018070140A2
BR112018070140A2 BR112018070140A BR112018070140A BR112018070140A2 BR 112018070140 A2 BR112018070140 A2 BR 112018070140A2 BR 112018070140 A BR112018070140 A BR 112018070140A BR 112018070140 A BR112018070140 A BR 112018070140A BR 112018070140 A2 BR112018070140 A2 BR 112018070140A2
Authority
BR
Brazil
Prior art keywords
oil
thickener
methods
active agent
organic solvent
Prior art date
Application number
BR112018070140A
Other languages
English (en)
Inventor
Hnat Thomas
Original Assignee
Smartech Topical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smartech Topical Inc filed Critical Smartech Topical Inc
Publication of BR112018070140A2 publication Critical patent/BR112018070140A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

de acordo com um aspecto da presente divulgação, são fornecidas formulações que compreendem: (a) pelo menos um agente ativo; (b) um óleo e, opcionalmente, um espessante para este fim; (c) um solvente orgânico e um espessante para este fim; e (d) um potencializador de penetração na pele solúvel em óleo e/ou solvente; em que: a referida formulação compreende < 10% em peso de água; e a referida formulação forma, opcionalmente, um gel diluente tixotrópico. são também fornecidos géis que compreendem óleo e solvente orgânico, métodos para prepará-los e métodos para distribuição tópica de um agente ativo a um sujeito em necessidade do tratamento.
BR112018070140A 2016-03-31 2017-03-31 sistema de distribuição BR112018070140A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662316064P 2016-03-31 2016-03-31
PCT/US2017/025373 WO2017173269A1 (en) 2016-03-31 2017-03-31 Delivery system

Publications (1)

Publication Number Publication Date
BR112018070140A2 true BR112018070140A2 (pt) 2019-02-05

Family

ID=59965231

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018070140A BR112018070140A2 (pt) 2016-03-31 2017-03-31 sistema de distribuição

Country Status (13)

Country Link
US (2) US11666531B2 (pt)
EP (1) EP3435978A4 (pt)
JP (1) JP2019510824A (pt)
KR (1) KR20190003535A (pt)
CN (1) CN109414405A (pt)
AU (1) AU2017240680A1 (pt)
BR (1) BR112018070140A2 (pt)
CA (1) CA3019582A1 (pt)
EA (1) EA201892156A1 (pt)
MX (1) MX2018011881A (pt)
PH (1) PH12018502036A1 (pt)
SG (1) SG11201808231VA (pt)
WO (1) WO2017173269A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017025582A1 (en) 2015-08-13 2017-02-16 Basf Se Nonaqueous pesticide suspension comprising a water soluble solvent, an inorganic thickener, and an alkoxylate
DE102016107563A1 (de) * 2016-04-22 2017-10-26 Sven Reichwagen Vitaminzubereitung
US11617727B2 (en) 2019-04-30 2023-04-04 Bayer Healthcare Llc Topical analgesic gel compositions
WO2020223097A1 (en) 2019-04-30 2020-11-05 Bayer Healthcare Llc Topical analgesic compositions
US12029707B2 (en) 2019-05-28 2024-07-09 Tech Swerve Llc Penetrating topical pain relief compositions and methods of use
EP3975703A4 (en) 2019-05-28 2023-07-12 Tech Swerve LLC PENETRATING TOPICAL PAIN RELIEF COMPOSITIONS AND METHODS OF USE
WO2020252252A1 (en) 2019-06-14 2020-12-17 Propella Therapeutics, Inc. Topical acyclovir formulations and uses thereof
US10842758B1 (en) * 2019-06-18 2020-11-24 Ampersand Biopharmaceuticals, Inc. Transdermal penetrant formulations containing cannabidiol
MA56543A (fr) * 2019-06-18 2022-04-27 Dyve Biosciences Inc Formulations de pénétration transdermique
EP3999032A4 (en) 2019-07-16 2023-08-30 Donaghys Limited TRANSDERMAL SOLVENT SYSTEM AND METHOD OF USE
AU2020379828A1 (en) 2019-11-06 2022-04-28 Smartech Topical, Inc. Topical formulations of cyclooxygenase inhibitors and their use
US11213467B2 (en) * 2019-11-07 2022-01-04 Amyris, Inc. Compositions and methods for delivering cannabinoids to skin
MX2022005571A (es) * 2019-11-07 2022-06-09 Amyris Inc Composiciones y metodos para administrar cannabinoides a la piel.
CN110917053A (zh) * 2019-12-06 2020-03-27 辉达生物医药（苏州）有限公司 一种抗炎组合物
WO2021155398A1 (en) 2020-01-28 2021-08-05 Mary Kay Inc. Lip composition
CN113827547A (zh) * 2020-06-23 2021-12-24 南京清普生物科技有限公司 一种缓释制剂组合物
CA3189272A1 (en) * 2020-08-17 2022-02-24 Zhiwen Tang Long acting in-situ forming/gelling compositions
US20240060807A1 (en) * 2020-12-07 2024-02-22 Smartech Topical, Inc. Liquid dispensing valve device
US20250195409A1 (en) * 2021-04-09 2025-06-19 Ananda Scientific, Inc. Methods for improving cutaneous permeation of cannabinoids and fatty acid amides
EP4333826A4 (en) * 2021-05-05 2025-03-12 Smartech Topical Inc TOPICAL FORMULATIONS OF NAPROXEN AND THEIR USE

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63225312A (ja) 1986-10-02 1988-09-20 Kao Corp 透明ないし半透明のジエリー状の化粧料
US5002938A (en) 1988-03-21 1991-03-26 Bristol-Myers Squibb Company Antifungal gel formulations
US8980290B2 (en) * 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US7618651B2 (en) 2004-06-24 2009-11-17 Idexx Laboratories Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same
JP2006265153A (ja) * 2005-03-23 2006-10-05 Noevir Co Ltd ゲル組成物
CN101296691B (zh) * 2005-08-05 2011-07-27 努沃研究公司 透皮释药剂型
NZ577020A (en) * 2006-10-17 2012-05-25 Nuvo Res Inc Diclofenac gel containing dimethyl sulfoxide (dmso)
PT2211837E (pt) * 2007-06-08 2014-02-17 Troikaa Pharmaceuticals Ltd Uma solução tópica não aquosa de diclofenaco e processo para preparar a mesma
EP2306965B1 (en) 2008-08-09 2015-12-02 Merck Patent GmbH Use of indole compounds as a cosmetic
JP5965319B2 (ja) 2009-10-22 2016-08-03 エイピーアイ・ジェネシス，エルエルシー フラボノイド含有組成物の製造方法及び使用
JP5650239B2 (ja) * 2009-12-04 2015-01-07 コルゲート・パーモリブ・カンパニーＣｏｌｇａｔｅ−Ｐａｌｍｏｌｉｖｅ Ｃｏｍｐａｎｙ 固体の高充填を強化するための、ポリソルベート等の高濃度の非イオン界面活性剤を含む溶解性フィルム
CA2792018A1 (en) * 2010-05-10 2011-11-17 Segetis, Inc. Fragrant formulations, methods of manufacture thereof and articles comprising the same
US9504664B2 (en) * 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
MX365427B (es) 2011-05-03 2019-06-03 Aponia Laboratories Inc Composiciones transdermicas de ibuprofeno y metodos de uso de las mismas.
EP2790670A1 (en) * 2011-12-12 2014-10-22 Leo Laboratories Limited Gel compositions
CN102652730B (zh) * 2012-03-29 2014-04-16 武汉华大药业有限公司 软膏基质、苦参绿茶软膏及其制备方法
US8822537B2 (en) * 2012-09-27 2014-09-02 Achelios Therapeutics, Inc. Topical ketoprofen composition
EP2922542A4 (en) 2012-11-21 2016-10-05 Topokine Therapeutics Inc METHODS AND COMPOSITIONS FOR LOCALLY INCREASING BODY FAT
CA3179312A1 (en) * 2013-03-15 2014-09-18 Vapogenix, Inc. Analgesic compositions comprising halogenated volatile compounds
US9012402B1 (en) 2014-06-11 2015-04-21 James Blanchard Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation

Also Published As

Publication number Publication date
SG11201808231VA (en) 2018-10-30
EP3435978A1 (en) 2019-02-06
KR20190003535A (ko) 2019-01-09
AU2017240680A1 (en) 2018-11-15
US20230310318A1 (en) 2023-10-05
MX2018011881A (es) 2018-12-17
EA201892156A1 (ru) 2019-03-29
CA3019582A1 (en) 2017-10-05
PH12018502036A1 (en) 2019-07-15
CN109414405A (zh) 2019-03-01
WO2017173269A1 (en) 2017-10-05
EP3435978A4 (en) 2019-12-11
JP2019510824A (ja) 2019-04-18
US20190046438A1 (en) 2019-02-14
US11666531B2 (en) 2023-06-06

Similar Documents

Publication Publication Date Title
BR112018070140A2 (pt) sistema de distribuição
BR112017023380A2 (pt) sistema, composição cosmética, métodos para tratamento de substratos queratinosos e para proteção e/ou alisamento da fibra do cabelo, kit multicompartimento, e, processo para alisamento do cabelo.
CL2017003307A1 (es) Sistema de administración dirigida de principio activo celular
CO7240372A2 (es) Formulaciones farmacéuticas tópicas no acuosas
BR112016028961A8 (pt) fibras eletrotorcidas, seu método de preparação e seu uso, bem como composição, e kit
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
CR20140365A (es) Compuestos de carbamato y preparación y uso de los mismos
BR112015019657A8 (pt) composições tópicas, kit e método para aumentar a liberação de óxido nítrico a partir de um gel tópico anidro contendo uma macromolécula modificada de diazeniodiolato
BR112015031608A2 (pt) Aplicação e uso dos sistemas crispr-cas, vetores e composições para direcionamento e terapia hepáticos
BR112019001253A2 (pt) composto, composição farmacêutica, e, métodos de tratamento de câncer ou de atrofia muscular e de doença de parkinson.
EA201691808A1 (ru) Кортикостероидные композиции для местного применения
AR096127A1 (es) Composición, uso y sistema de fertirrigación
BR112019006880A2 (pt) compostos e composições para tratamento de leishmaniose e métodos de diagnóstico e tratamen-to usando os mesmos
BR112018001213A2 (pt) composição de fragrância à base de água, dispositivo de entrega de fragrância, e método para fornecer um perfume de longa duração
BR112017004738A2 (pt) sistema de distribuição de agroquímicos baseados em híbridos de peg-dendron anfifílicos responsivos à enzima ou ao ph
BR112016006830A2 (pt) composição de spray tópico de halobetasol, sistema de distribuição para a administração da composição, processo para a preparação de uma composição de spray tópico, método para o tratamento de condições de pele tópicas
BR112017000312A2 (pt) sistema de tratamento da saúde bucal para a aplicação de fosfato de cálcio amorfo, uso de um ou mais aminoácidos básicos, composição, e uso de um ou mais aminoácidos em um sistema de tratamento da saúde bucal
BR112018001486A2 (pt) ?composição de limpeza em barra, processo para preparar a composição, método para reduzir atividade antimicrobiana em uma superfície e uso da composição?
CL2020000221A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
CO2017003787A2 (es) Limoneno: formulación y uso insecticida
CL2020000551A1 (es) Formulación de uso tópico para el control y la prevención de parásitos en animales.
BR112016029278A2 (pt) composição cosmética compreendendo um polímero espessante que tem porções hidrofóbicas e hidrofílicas
NI201500007A (es) Formulación transdérmica que contiene inhibidores de cox
BR112015025968A2 (pt) poliplexos
CL2018002200A1 (es) Administración combinada de un agente de penetración y un compuesto de azufre que contiene compuesto para las plantas.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]
B11R Patent application dismissed according to article 229 of the patent law [chapter 11.18 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2664 DE 25-01-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.